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Abstract: Here we provide an overview of the rationale and methods of a series of planned 
population based studies within the Danish Centre for Strategic Research in Type 2 Diabetes 
(DD2)  Project. The project aims to support and evaluate ongoing political and administrative 
efforts to implement nationwide guidelines for maintaining metabolic control in newly diagnosed 
type 2 diabetes (T2D) patients to prevent diabetic complications and improve quality of life. The 
DD2 is designed as a prospective cohort study (collection of epidemiological data) supplemented 
by randomized clinical intervention trials (on physical exercise and individualized pharmacologi-
cal treatment) and the establishment of a biobank comprised of material from a large number 
of newly diagnosed T2D patients. Inclusion of the majority of newly diagnosed T2D patients 
as they are diagnosed at their general practitioner or diabetes hospital outpatient clinics and 
entered into the DD2 cohort will establish a nationwide database comprising a large number of 
future incident cases of T2D in Denmark. These cases will form the project cohort of the DD2. 
Within the first 6 months of diagnosis, all patients will be invited to contribute to a biobank of 
DNA, plasma, urine, and tissue sampling. The DNA biobank will enable future studies of the 
effect of pharmacological treatment and outcome in subsets of patients with specific genetic 
risk profiles covering disease etiology and specific drug kinetics and metabolism. We will also 
perform two clinical intervention trials examining: the effectiveness of physical exercise on 
diabetes-related outcomes and the impact of trial outcomes on individualized pharmacological 
treatment. Moreover, the DD2 will serve as a platform for testing and developing new antidi-
abetic drugs. All together, we expect this study to contribute to substantially improved diabetes 
care in T2D patients locally and abroad.
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Background and rationale of the planned studies
Genetic predictors
The incidence of type 2 diabetes (T2D) is increasing. The disease often carries severe 
complications. Since 1992, several genetic subtypes of monogenetic diabetes have 
been described in which gene mutations result in diabetes primarily through beta-cell 
dysfunction.1–4 This new knowledge means that patients who were previously catego-
rized clinically as having maturity-onset diabetes of the young (MODY), permanent 
neonatal diabetes mellitus, or transient neonatal diabetes mellitus, can now be classified 
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by genetic subgrouping. Definition of the genetic subgroup 
can result in appropriate treatment, genetic counseling, and 
prognostic information. In contrast, until recently, progress 
in identifying the genetic variants influencing predisposition 
to polygenic and much more common forms of T2D has 
been slow.  However, recent advances have begun to alter the 
 situation. Well-powered candidate gene studies and a number 
of genome-wide association studies have extended the  number 
of genetic loci to 20 harboring common variants that are 
implicated in  diabetes susceptibility. Furthermore, a number 
of loci associated with obesity, dyslipidemia, hypertension, 
and cardiovascular  disease have been identified. Some of these 
gene variants seem to offer new avenues for clinical translation. 
Recently, genetic variation was established to alter the response 
to therapy in T2D. Carriers of the T2D TCF7L2 rs7903146 
T-allele showed a decreased response to sulfonylureas but 
not to metformin.5 Most of the recently identified variants 
seem to affect beta-cell function,6 but the fat mass and 
obesity-associated gene (FTO)-variants have been shown to 
influence T2D risk through a primary effect on weight and 
obesity. Interestingly, the impact of the FTO variants on risk 
of obesity and T2D seems to be influenced by level of  physical 
 exercise. Physical inactivity is associated with decreased 
insulin sensitivity and a body mass index increase of nearly 
2 kg/m2 in those carrying two risk  variants, whereas no major 
effect of sedentary lifestyle were found among noncarriers of 
FTO risk variants.7,8 Thus, the identification of new genes and 
pathways responsible for T2D predisposition and increased risk 
of diabetic complications offers  opportunities for developing 
novel therapeutic and p reventive approaches. Furthermore, the 
identification of additional genetic variants, both  protective 
and those increasing risk, may render it  possible to use pat-
terns of predisposition to tailor individual management of 
these conditions.
Physical exercise
One key intervention in the treatment of T2D is lifestyle 
change. In this respect, dietary interventions are based 
on solid scientific data9 but it is presumed that increased 
physical activity is also an important part of treatment in 
T2D patients. This is indicated by the recent report from 
The Danish  Commission on Prevention (www.forebyg-
gelseskommisionen.dk/files/f iler/faktaark_motion.pdf) 
recommending exercise training by prescription to subjects 
at high risk including T2D patients. Although studies have 
shown that the onset of T2D may be postponed by around 
2 years by physical exercise when implemented in the 
prediabetic stage (impaired glucose tolerance),9–11 it has 
never been documented that patients with overt T2D are 
able to increase their level of physical  exercise over longer 
periods and it remains unknown if physical exercise training 
may improve quality of life, reduce diabetic complications, 
and prolong life expectancy when initiated in patients with 
overt T2D.
Individualized pharmacological treatment
One problem related to improvement in the outcome of T2D 
is that the algorithms for pharmacological treatment are not 
individualized but are based on cohort studies and applied 
to patients in general, independent of the fact that T2D is a 
very heterogeneous disease with different pathophysiologi-
cal defects underlying hyperglycemia. Some patients recog-
nized as T2D (about 10%) suffer from latent autoimmune 
diabetes in adults (LADA), a disease destroying beta-cells, 
and others suffer from monogenetic MODY forms (about 
1%–2%). However, around 80% of T2D patients develop 
 hyperglycemia due to multifactorial and multigenetic 
 factors.12 Most – but not all – patients are insulin resistant, 
whereas in other patients the beta-cell defects are dominant. 
In those situations, different genetic defects may be involved 
so both the genotype and the phenotype must be character-
ized to apply the appropriate treatment and, as a minimum, 
the degree of insulin resistance, beta-cell capacity, degree of 
autoimmunity, gene variants, and the metabolic profile must 
be measured in newly diagnosed T2D patients to optimize 
the therapeutic intervention. In “conventional” evidence-
based medicine, most data are generated from large clinical 
intervention trials treating all subjects in the same way eg, 
with a specific drug.13–17 However, it is often not recognized 
that even if the intervention group performed better than 
the control group, it does not prove conclusively that all 
subjects will benefit from the intervention; some may in 
fact be harmed. Nevertheless, we used these data to develop 
algorithms for treatment of all T2D patients as if they were 
a homogenous group. Thus, this study differs from stud-
ies such as ADVANCE18 and ACCORD19 in that it is not a 
randomized controlled trial but individualized algorithms 
based on  specific characterization of the individual genotype. 
Phenotype will be tested prospectively in specific cohorts.
To prevent T2D and improve treatment of the metabolic 
abnormalities behind the disease, with the main aim of pre-
venting complications, cost-effective national organization 
and intervention are needed. The individualized treatment 
described is costly, but it is our experience, based on the 
Funen model project,20 that correct treatment costs less in 
the long-term. Thus, although intervention against diabetic 
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complications may be expensive, it will be cost-effective 
in the long-term since treatment of severe complications is 
even more costly. With this in mind, health economics will 
be an important part of the DD2 study.
Design and methods of the planned 
studies
The DD2 project will consist of two parts: a large population-
based prospective cohort study including the establishment of 
databases and a biobank that will allow a number of ensuing 
nested case-control studies and clinical intervention. The 
DD2 aims to include most newly diagnosed T2D patients 
from 2010 to 2015 – that is, about 50,000 patients. In the 
population-based cohort study, we will follow patients over 
time for diabetes outcomes including their use of medications, 
hospital contacts and diagnoses of diabetic complications, 
surgical procedures, dialysis, socioeconomic prognosis, and 
total and cause-specific mortality. We will examine predictors 
of metabolic results and clinical endpoints (late diabetic 
complications and mortality), including genetic predictors by 
using a new biobank of DNA. Also we will examine a subset 
of patients with specific genetic risk profiles covering disease, 
etiology and specific drug genetics as well as metabolism, 
including non-DNA biomarkers. In the clinical interven-
tion part, we will test the hypothesis that physical exercise 
is an important part of treatment of T2D and investigate the 
importance of individualized pharmacological treatment 
and the cost-effectiveness of this kind of treatment. Finally, 
beside these projects, we aim to develop a platform for test-
ing and developing new antidiabetic drugs. This part will be 
carried out in collaboration with Novo Nordisk, Copenhagen, 
Denmark.
Establishing a nationwide cohort of future 
incident cases of T2D and following them 
in Danish registries
To conduct this nationwide cohort study in Denmark, we 
will use the unique Danish registration system. The logistics 
of patient enrollment in the DD2 from general practitioners 
and hospital outpatient clinics have been described in detail 
by Nielsen et al.21 The Danish National Registry of Patients 
covers all hospitals serving the entire Danish population 
of 5.5 million people. The records include dates of hos-
pital admission and discharge, type and date of surgical 
procedures performed since 1977, and up to 20 discharge 
diagnoses, classified according to the International Classifi-
cation of Diseases, 8th revision (ICD-8) until December 31, 
1993, and 10th revision thereafter (ICD-10)22. In all Danish 
registries, patients are identified by their civil registration 
numbers. These unique identifiers assigned at birth or at 
immigration are stored in the Danish civil registration sys-
tem – a nationwide registry of all persons residing in Den-
mark since April 1, 1968 – along with birth date, residency 
status, and dates of immigration, emigration, and death (if 
any). The registration number identifies the patient in all 
health registries thus enabling linkage and complete follow 
up data achieved from a number of data sources. These 
include comorbidities from the National Registry of Patients 
and pharmacological treatment from the Danish Registry 
of Medical Products Statistics. Furthermore, it is possible 
to link with nationwide laboratory databases to ascertain 
the quality of diabetes care in Denmark, for example, to 
the The Danish Diabetes Database for Adults,20,21,23 as well 
as to other relevant health and demographic databases. The 
Danish registration system makes possible a comprehensive 
follow-up on clinical endpoints on each patient in the DD2 
cohort.24
The Danish health care system and 
application of national diabetes guidelines
The Danish health care system can be used free at the point 
of delivery by everybody who is a permanent resident in 
 Denmark, as described in more detail elsewhere.21 This 
includes diabetes care. All permanent residents receive a 
national health insurance card that works as an identity card 
and must be presented at all visits to doctors, emergency 
rooms, and hospitals. The five regions of Denmark are 
responsible for providing hospital care and own and run 
their own hospitals, outpatient clinics, and prenatal care 
centers. The regions also finance general practitioners, 
specialists, physiotherapists, dentists, and pharmaceuticals. 
Self-employed general practitioners act as gatekeepers to 
secondary care; thus, all patients have to be referred to 
 hospital or outpatients clinics by their general practitioner 
for specialized diagnosis, treatment, and care.
Vital to the DD2 project is the inclusion of a major 
proportion of new diabetes cases, as they are registered 
with this diagnosis by their general practitioner or at public 
 hospitals. These cases will form the project database. The 
DD2 project aims to support ongoing political and admin-
istrative efforts to implement nationwide guidelines. The 
goal of these guidelines is to provide referral of all patients 
who are newly diagnosed with T2D to a hospital diabetes 
outpatient clinic for registration and participation in a 
 diabetes education  program.  Application of such universal 
guidelines will minimize referral bias and reduce variability 
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in the quality of initial primary care. Thus, one of the goals 
is the establishment of an efficient, centralized, and uniform 
registration of all incident cases, whereby risk values and 
clinical outcome can be followed continuously and used 
for instruction.
Establishing a repository of biomaterials 
from patients with incident cases of T2D
Within the first 6 months of diagnosis, all patients registered 
as incident cases will be invited to contribute to a DNA 
biobank. After signing a statement of consent, patients 
will be asked to provide a blood and urine sample at their 
general practitioner or at the diabetes outpatient clinic, 
which will be stored at the biobank, and to fill out a short 
 questionnaire. The Danish registration system allows us to 
recover, at regular intervals, data on lipid profiles, blood 
pressure, glycemic control, and body composition of 
patients enrolled in the DD2 project, and these data sources 
will be used to follow patients over time. As additional 
data can be retrieved, patients need only visit an outpatient 
diabetes clinic or their general practitioner clinic once to be 
fully enrolled in the DD2 project. (For further information 
about implementations and logistics see Nielsen et al.)21
Genomic DNA will be genotyped in the entire cohort, 
with a focus on known risk variants for T2D. If relevant, it 
will also be sequenced for the identification of new variants 
important for outcome. Variants proven associated with 
obesity, dyslipidemia, hypertension, and cardiovascular dis-
ease will be genotyped. We plan to test the effects of both 
individual gene variants and combinations of gene variants 
on drug response and the development of micro- and mac-
rovascular complications. Further, we will examine whether 
the effects of early intensified physical exercise is modified 
by specific variants. For biomarkers other than DNA, after 
identification of incident cases (at 6-month intervals in The 
Danish National Registry of Patients), a centralized random-
ization procedure will identify half of the study population, 
who will then be invited to contribute to a bioregistry of 
blood samples. We will specifically measure fasting plasma 
C-peptide to monitor beta-cell function and glutamic acid 
decarboxylase antibodies to monitor autoimmunity, as well as 
other molecules related to insulin resistance, such as fasting 
Table 1 Timescale for The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Project
Year 2011 Year 2012 Year 2013 Year 2014 Year 2015
Jan Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar
Event
Patient enrollment into DD2.
Registration of newly diagnosed  
T2D subjects for the first year  
should be finalized; samples  
should be collected and stored  
at either Vejle Hospital or the  
National Institute for Health Data  
and Disease Control; start of the  
intervention studies. Methods for 
recruitment established.
Registration of newly diagnosed  
T2D subjects for the first year  
should be finalized; samples should  
be collected and stored at either  
Vejle Hospital or National Institute 
for Health Data and Disease  
Control; start of the intervention  
studies. Methods for recruitment  
established.
Development of the second clinical 
report; end of intervention studies  
on individualized treatment.
Development of the third clinical  
report; end of the physical  
training trial
Reporting of main results from  
the DD2 study.
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serum insulin. This material will allow analysis of proteins 
or small molecule biomarkers.
Clinical intervention study: randomized 
clinical substudies
Effects of an early physical exercise program
Lifestyle changes, such as dietary interventions and 
increased physical exercise, are proposed as important and 
one of the key interventions in the treatment of T2D.10,11 
The Danish Commission on Prevention recommends the 
prescription of exercise training to subjects at high risk of 
or with T2D. In Denmark, the municipalities are responsible 
for population-directed preventative efforts to increase the 
level of physical exercise. We expect 40% of the munici-
palities in Denmark will  volunteer to join this DD2 sub-
study; thus, we expect to include a minimum of 5000 T2D 
patients over 2 or more years. All interested municipalities 
will be instructed in different methods to enhance the level 
of physical exercise. Ten  representative municipalities 
will be selected to join an “interval  walking” program. 
The remaining municipalities will serve as controls. After 
5 years of intervention, we will investigate whether physi-
cal exercise has lowered the risk of cardiovascular disease 
among T2D patients.
Individualized pharmacological treatment
During the DD2, we will set up prospective studies in cohorts 
to test the importance of individually tailored treatment 
based on the pathophysiological characterization of each 
subject. In this respect, we wish to characterize T2D patients 
with  autoimmunity – that is, glutamic acid decarboxylase 
 antibodies – termed “LADA,” and patients with specific 
MODY subtypes. These patients will be offered a specific 
treatment based on pathophysiological characterization. 
LADA patients will be randomized to either the general 
national algorithm or early insulin treatment. In the MODY 
group, treatment will be individualized based on genotype, 
since each genotype group has its own prognosis. The 
remaining DD2 patients in this case will also be treated in 
accordance with the general guidelines. In both the LADA 
and MODY intervention trials, the number of patients will 
be too small for clinical endpoint trials (some 5%–10% of 
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the diabetes population) and  metabolic criteria will thus be 
used, for example, HbA
1c
, blood pressure,  lipids, and urine 
albumin excretion. In the large group of non-LADA and 
non-MODY patients (80% of all T2D patients), two major 
phenotypes seem to be  present (as defined by the World 
Health Organization); namely, patients with severe insu-
lin resistance (defined by homeostasis model  assessment 
 estimates) and patients with normal insulin sensitivity, but 
severe defects in insulin secretion (here defined by the fasting 
plasma C-peptide  concentration). Patients with severe insulin 
resistance (25% of the upper quartile) will be identified and 
randomized to treatment with insulin sensitizers,  combined 
with dipeptidyl peptidase IV inhibitors or  glucagon-like pep-
tide-1 analogs if needed, or to the  general national guidelines 
standard treatment suggested by national guidelines. As we 
will also be involved with small groups, we will focus on 
metabolic outcome data, as  previously stated. Patients suf-
fering from severe beta-cell defects (ie, with fasting plasma 
C-peptide , 300 pmol/L) will be randomized to insulin 
treatment or the general guideline algorithm and evaluated as 
described for the insulin-resistant subjects. Based on a power 
calculation, with each study running for 2 years, an expected 
reduction in HbA1c of 0.4% requires more than 250 patients 
in each project arm. Testing our hypothesis of individualized 
treatment may enable us to develop a more adequate algorithm 
for the pharmaceutical treatment of T2D patients.
Use of results and timescale
Based on the updated results from the survey, the investiga-
tors will ensure immediate translation of the results into more 
individual clinical guidelines for the daily treatment and 
monitoring of T2D. The annual reports will include detailed 
health economics cost–benefit analyses and will be forwarded 
to the National Steering Committee of the Danish National 
Board of Health for implementation in new guidelines.
The timescale for the DD2 project is described in 
Table 1.
Conclusion
The overall aim of the project is to near-normalize meta-
bolic control in newly diagnosed T2D patients to prevent 
complications and improve quality of life by continuously 
developing and implementing guidelines and organizational 
plans as results emerge from epidemiological and interven-
tional substudies. Systematic follow-up will be performed 
continuously and through the participation of both scientific 
and regulatory bodies guidelines will evolve on all levels, 
individually and nationally.
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